While a recent study of salvage radical prostatectomy after focal therapy demonstrates satisfactory functional outcomes, oncologic outcomes were not as good as after primary RP, said researcher Jaime O. Herrera-Caceres, MD.
Cheryl Guttman Krader
An analysis of trends in the management of renal masses shows growing use of active surveillance, although some data suggest “a proportion of surveillance cases may have been due to lack of access to care instead of truly choosing active surveillance,” says study author Ketan K. Badani, MD.
A private urology practice can successfully transform itself from a fee-for-service payment model for cancer care to an episode-based system, although it remains to be determined whether operating under this model also translates into cost savings.
“Patients should be informed of the less-than-ideal stone-free rates and secondary morbidity when residual fragments are present after this treatment modality,” says researcher Igor Sorokin, MD.
The analysis “gives urologists the first accurate idea of how many physician assistants and nurse practitioners are working in urology,” says researcher Raymond Fang.
New study findings provide evidence to guide management decisions for patients with prostate cancer who have lymph node metastases following radical prostatectomy.
Findings from a cost-effectiveness analysis provide useful information for physicians, patients, and payers about available treatments for lower urinary tract symptoms due to BPH, according to the authors who conducted it.
Analyses of data from 5 years of prospective follow-up in the pivotal trial supporting regulatory approval of the prostatic urethral lift ([PUL] UroLift System, NeoTract) show that the minimally invasive procedure remains safe and provides rapid and durable benefits for men with symptomatic BPH.
Patients undergoing ureteroscopy while remaining on anticoagulant therapy may be at increased risk for bleeding complications, including significant bleeding events and unplanned returns to the operating room, according to a retrospective study
Results from bench studies favor a new open-faced stone retrieval device (Dakota, Boston Scientific) for having greater versatility, efficacy, and durability compared with a competing product, and the in vitro performance of the new instrument is consistent with early clinical experience, says Roger L. Sur, MD.